{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:44:19Z","timestamp":1793105059765,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","award":["OPP1108403"],"award-info":[{"award-number":["OPP1108403"]}],"id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP11154739"],"award-info":[{"award-number":["OPP11154739"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>New strategies are needed to reduce the incidence of malaria, and promising approaches include the development of vaccines and monoclonal antibodies (mAbs) that target the circumsporozoite protein (CSP). To select the best candidates and speed development, it is essential to standardize preclinical assays to measure the potency of such interventions in animal models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Two assay configurations were studied using transgenic\n                      <jats:italic>Plasmodium berghei<\/jats:italic>\n                      expressing\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      full-length circumsporozoite protein. The assays measured (1) reduction in parasite infection of the liver (liver burden) following an intravenous (i.v) administration of sporozoites and (2) protection from parasitaemia following mosquito bite challenge. Two human CSP mAbs, AB311 and AB317, were compared for their ability to inhibit infection. Multiple independent experiments were conducted to define assay variability and resultant impact on the ability to discriminate differences in mAb functional activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, the assays produced highly consistent results in that all individual experiments showed greater functional activity for AB317 compared to AB311 as calculated by the dose required for 50% inhibition (ID50) as well as the serum concentration required for 50% inhibition (IC50). The data were then used to model experimental designs with adequate statistical power to rigorously screen, compare, and rank order novel anti-CSP mAbs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results indicate that in vivo assays described here can provide reliable information for comparing the functional activity of mAbs. The results also provide guidance regarding selection of the appropriate experimental design, dose selection, and group sizes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-020-03181-0","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T09:02:47Z","timestamp":1584435767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein"],"prefix":"10.1186","volume":"19","author":[{"given":"Rama","family":"Raghunandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan T.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevel","family":"Flores-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica W.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Jhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Perez-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Richter","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidel","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"3181_CR1","unstructured":"WHO. World Malaria Report. Geneva: World Health Organization; 2018. https:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2018\/report\/en\/."},{"key":"3181_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s13063-019-3391-7","volume":"20","author":"M Van Den Berg","year":"2019","unstructured":"Van Den Berg M, Ogutu B, Sewankambo KN, Andorno BN, Tanner M. RTS, S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials. Trials. 2019;20:316.","journal-title":"Trials."},{"key":"3181_CR3","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, et al. Seven-year efficacy of RTS, S\/AS01 malaria vaccine among young African children. N Engl J Med. 2016;374:2519\u201329.","journal-title":"N Engl J Med"},{"key":"3181_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4161\/hv.6.1.9677","volume":"6","author":"J Cohen","year":"2010","unstructured":"Cohen J, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S\/AS. Human Vaccines. 2010;6:90\u20136.","journal-title":"Human Vaccines."},{"key":"3181_CR5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White MT, Verity R, Griggin JT, Asante KP, Owusu-Agyei S, Greenwood B, et al. Immunogenicity of the RTS, S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet. 2015;15:1450\u20138.","journal-title":"Lancet"},{"key":"3181_CR6","doi-asserted-by":"publisher","first-page":"46621","DOI":"10.1038\/srep46621","volume":"7","author":"AK Collins","year":"2017","unstructured":"Collins AK, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 2017;7:46621.","journal-title":"Sci Rep."},{"key":"3181_CR7","doi-asserted-by":"crossref","unstructured":"Venkatraman N, Tiono A, Bowyer G, Powlson J, Collins K, Coulibaly S, Hill A, et al. Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers. MedRxI. 2019;medRxiv 19009282.","DOI":"10.1101\/19009282"},{"key":"3181_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"R Seder","year":"2013","unstructured":"Seder R, Chang LJ, Enama M, Zephir KL, Sarwar U, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359\u201365.","journal-title":"Science"},{"key":"3181_CR9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2409595","volume":"228","author":"F Zavala","year":"1985","unstructured":"Zavala F, Tam JP, Hollingdale MR, Cochrane AH, Quakyi I, Nussenzweig RS, et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985;228:1436\u201340.","journal-title":"Science"},{"key":"3181_CR10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.immuni.2017.11.007","volume":"47","author":"G Triller","year":"2017","unstructured":"Triller G, Scally SW, Costa G, Pissarev M, Kreschel C, Bosch A, et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity. 2017;47:1197\u2013209.","journal-title":"Immunity"},{"key":"3181_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.aar5304","volume":"360","author":"K Imkeller","year":"2018","unstructured":"Imkeller K, Scally SW, Bosch A, Marti GP, Costa G, Triller G, et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science. 2018;360:1358\u201362.","journal-title":"Science."},{"key":"3181_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20170869","volume":"215","author":"SW Scally","year":"2018","unstructured":"Scally SW, Murugan R, Bosch A, Triller G, Costa G, Mordm\u00fcller B, et al. Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. J Exp Med. 2018;215:63\u201375.","journal-title":"J Exp Med"},{"key":"3181_CR13","first-page":"1098","volume":"10","author":"BJ Booth","year":"2018","unstructured":"Booth BJ, Ramakrishnan B, Narayan K, Wollacott AM, Babcock GJ, Shriver Z, Visawanathan K. Extending human IgG half-life using structure-guided design. MABS. 2018;10:1098\u2013110.","journal-title":"MABS."},{"key":"3181_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-immunol-042617-053301","volume":"37","author":"J Tan","year":"2019","unstructured":"Tan J, Piccoli L, Lanzavecchia A. The antibody response to Plasmodium falciparum: cues for vaccine design and the discovery of receptor-based antibodies. Annu Rev Immunol. 2019;37:225\u201346.","journal-title":"Annu Rev Immunol"},{"key":"3181_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41577-019-0209-5","volume":"19","author":"JP Julien","year":"2019","unstructured":"Julien JP, Wardemann H. Antibodies against Plasmodium falciparum malaria at the molecular level. Nat Rev Immunol. 2019;19:761\u201375.","journal-title":"Nat Rev Immunol"},{"key":"3181_CR16","doi-asserted-by":"publisher","first-page":"10438","DOI":"10.1073\/pnas.1715812114","volume":"114","author":"D Oyen","year":"2017","unstructured":"Oyen D, Torres JL, Wille-Reece U, Ockenhouse CF, Emerling D, Glanville J, Volkmuth W, Flores-Garcia Y, et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA. 2017;114:10438\u201345.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3181_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018;24:408\u201316.","journal-title":"Nat Med"},{"key":"3181_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan J, Sack BK, Oyen D, Zenklusen I, Piccoli L, Barbieri S, et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat Med. 2018;24:401\u20137.","journal-title":"Nat Med"},{"key":"3181_CR19","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1128\/IAI.00461-13","volume":"81","author":"DA Espinosa","year":"2013","unstructured":"Espinosa DA, Yadava A, Angov E, Maurizio PL, Ockenhouse CF, Zavala F. Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect Immun. 2013;81:2882\u20137.","journal-title":"Infect Immun."},{"key":"3181_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12936-019-3055-9","volume":"18","author":"Y Flores-Garcia","year":"2019","unstructured":"Flores-Garcia Y, Herrera SM, Jhun H, P\u00e9rez-Ramos DW, King CR, Locke E, et al. Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar J. 2019;18:26.","journal-title":"Malar J."},{"key":"3181_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3389\/fimmu.2018.00807","volume":"19","author":"NK Minkah","year":"2018","unstructured":"Minkah NK, Schafer C, Kappe SHI. Humanized mouse models for the study of human malaria parasite biology, pathogenesis, and immunity. Front Immunol. 2018;19:807.","journal-title":"Front Immunol."},{"key":"3181_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41541-017-0028-2","volume":"9","author":"BK Sack","year":"2017","unstructured":"Sack BK, Mikolajczak SA, Fishbaugher M, Vaughan AM, Flannery EL, Nguyen T, et al. Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice. NPJ Vaccines. 2017;9:27.","journal-title":"NPJ Vaccines."},{"key":"3181_CR23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/infdis\/jiw237","volume":"214","author":"JA Regules","year":"2016","unstructured":"Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, et al. Fractional third and fourth dose of RTS, S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis. 2016;214:762\u201371.","journal-title":"J Infect Dis"},{"key":"3181_CR24","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/s41467-017-01924-3","volume":"8","author":"SW Scally","year":"2017","unstructured":"Scally SW, McLeod B, Bosch A, Miura K, Liang Q, Carroll S, et al. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25. Nat Commun. 2017;8:1568.","journal-title":"Nat Commun."},{"key":"3181_CR25","first-page":"317","volume":"148","author":"S Suissa","year":"1985","unstructured":"Suissa S, Shuster J. Exact unconditional sample sizes for the 2\u2009\u00d7\u20092 binomial trial. J R Stat Soc. 1985;148:317\u201327.","journal-title":"J R Stat Soc."},{"key":"3181_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","volume":"43","author":"T Hothorne","year":"2003","unstructured":"Hothorne T, Lausen B. On the exact distribution of maximally selected rank statistics. Computational Stat Data Analysis. 2003;43:121\u201337.","journal-title":"Computational Stat Data Analysis."},{"key":"3181_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/biomet\/asp055","volume":"96","author":"I Kosimidis","year":"2009","unstructured":"Kosimidis I, Firth D. Bias reduction in exponential family nonlinear models. Biometrika. 2009;96:793\u2013804.","journal-title":"Biometrika"},{"key":"3181_CR28","unstructured":"R Core Team. A language and environment for staistical computing. Vienna. 2019, http:\/\/www.r-project.org\/index.html."},{"key":"3181_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, Machler M, Bolker B, Walker S. Fitting linear mixed effects models using Ime4. J Stat Softw. 2015;67:1\u201348.","journal-title":"J Stat Softw"},{"key":"3181_CR30","unstructured":"Ritz C, Strebig CJ. Analysis of dose-response curves. s.l.: CRAN, 2016. http:\/\/www.r-project.org."},{"key":"3181_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v028.i08","volume":"28","author":"T Hothorn","year":"2008","unstructured":"Hothorn T, Hornik K, van de Wiel AM, Zeileis A. Implementing a class of permutation tests: the coin package. J Stat Softw. 2008;28:1\u201323.","journal-title":"J Stat Softw"},{"key":"3181_CR32","unstructured":"Calhoun P. Exact: Unconditional Exact test. R package version 1.7. 2016, http:\/\/CRAN.R-project.org\/package+exact."},{"key":"3181_CR33","unstructured":"Wickham, H. Elegant graphics for data analysis. ggplot2. Springer. 2016, pp. ISBN 978-0-387-98141-3."},{"key":"3181_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-017-0011-y","volume":"2","author":"DA Espinosa","year":"2017","unstructured":"Espinosa DA, Christensen D, Munoz C, Singh S, Locke E, Zavala F. Robust antibody and CD8+\u2009T-cell responses induced by P falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection. NPJ Vaccines. 2017;2:1\u201310.","journal-title":"NPJ Vaccines."},{"key":"3181_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1084\/jem.20101488","volume":"208","author":"A Coppi","year":"2011","unstructured":"Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA, et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med. 2011;208:341\u201356.","journal-title":"J Exp Med"},{"key":"3181_CR36","doi-asserted-by":"publisher","first-page":"11340","DOI":"10.1111\/j.1462-5822.2006.00697.x","volume":"8","author":"O Silvie","year":"2006","unstructured":"Silvie O, Greco C, Franetich JF, Dubart-Kupperschmitt A, Hannoun L, van Germert GJ, et al. Expression of human CD81 differently affects host cell susceptibility to malaria sporozoites depending on the Plasmodium species. Cell Microbiol. 2006;8:11340\u20136.","journal-title":"Cell Microbiol"},{"key":"3181_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pt.2018.11.008","volume":"35","author":"K Dundas","year":"2018","unstructured":"Dundas K, Shears MJ, Sinnis P, Wright GJ. Important extracellular interactions between Plasmodium sporozoites and host cells required for infection. Trends Parasitol. 2018;35:129\u201339.","journal-title":"Trends Parasitol."},{"key":"3181_CR38","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1128\/IAI.01249-13","volume":"82","author":"BK Sack","year":"2014","unstructured":"Sack BK, Miller JL, Vaughan AM, Douglass A, Kaushanky A, Mikolajczak S, et al. Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infec Immun. 2014;82:808\u201317.","journal-title":"Infec Immun."},{"key":"3181_CR39","doi-asserted-by":"publisher","first-page":"aau8529","DOI":"10.1126\/sciadv.aau8529","volume":"4","author":"D Oyen","year":"2018","unstructured":"Oyen D, Torres JL, Cottrell CA, King CR, Wilson IA, Ward AB. Cryo-EM structure of P falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Sci Adv. 2018;4:aau8529.","journal-title":"Sci Adv."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03181-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-020-03181-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03181-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T20:18:46Z","timestamp":1615925926000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03181-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3181"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03181-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.19888\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19888\/v2","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"27 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiments were performed in accordance with the Guiding of Institutional Animal for Care and Use Committee at Johns Hopkins University, protocol number MO17H369.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FZ, YFG, SH, HJ, DPR, CRK, EL and RR have no conflict of interest. Not related to this manuscript, RG has received consulting income from Takeda, and has received research support from Janssen Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}